Cancer and Stem Cell Biology

癌症和干细胞生物学

• 批准号: 10394824
• 负责人: Gay M Crooks
• 金额: $ 15.53万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 1996
• 资助国家: 美国
• 起止时间: 1996-12-01 至 2025-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10394824
• 关键词: Achievement; Animal Model; Award; Behavior; Biological; Biological Models; Biological Process; Biology; Blood Vessels; Bone Marrow; Cancer Burden; Cancer Center Support Grant; Cancer Patient; Carcinoma; Catchment Area; Cells; Chemicals; Clinical; Collaborations; Colon Carcinoma; County; Development; Differentiation and Growth; Environment; Epithelial; Epithelial Cells; Extracellular Matrix; Faculty; Fibroblasts; Focus Groups; Fostering; Funding; Gays; Goals; Grant; Growth; Hair; Hematopoiesis; Hematopoietic; Hematopoietic stem cells; Homeostasis; Human; Immune; Immunotherapy; Inflammatory; Informal Social Control; Institution; Invaded; Jonsson Comprehensive Cancer Center of University of California Los Angeles; Journals; Lead; Legal patent; Lesion; Licensing; Link; Los Angeles; Lung; Lymphoid Cell; Lymphopoiesis; Malignant - descriptor; Malignant Neoplasms; Malignant lymphoid neoplasm; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Malignant neoplasm of prostate; Metabolism; Mitochondria; Modeling; Molecular; Natural regeneration; Oncogenic; Organoids; Pathway interactions; Peer Review; Process; Proliferating; Prostate; Publications; Recurrence; Regulation; Research; Research Personnel; Resource Sharing; Role; Schools; Science; Seeds; Signal Transduction; Signaling Molecule; Small Cell Carcinoma; Source; Stem Cell Research; Stem cell transplant; T-Lymphocyte; Technology; Thymus Gland; Tissues; Translating; Transplantation; Umbilical Cord Blood; United States National Institutes of Health; Work; base; cancer cell; cancer initiation; cancer therapy; chemotherapy; collaborative environment; engineered T cells; epithelial stem cell; human pluripotent stem cell; human tissue; inhibitor; insight; interest; leukemia/lymphoma; lung carcinogenesis; member; neoplastic cell; new therapeutic target; novel; peripheral blood; premalignant; programs; pyruvate carrier; recruit; repaired; self-renewal; small molecule; stem cell biology; stem cells; targeted biomarker; tissue stem cells; tool; translational scientist; tumor; tumor microenvironment

CANCER AND STEM CELL BIOLOGY RESEARCH PROGRAM (CSCB) ABSTRACT The Cancer and Stem Cell Biology Research Program (CSCB) is led by Director Gay Crooks, MBBS, who specializes in hematopoietic stem/progenitor cell transplantation and Co-Director Brigitte Gomperts, MD, who studies lung carcinogenesis and the role of the microenvironment. CSCB links basic and translational investigators studying biological processes shared between stem cells and malignancy. Program members expect that a detailed understanding of the mechanisms of normal and aberrant cell self-renewal and differentiation will reveal novel biological insights into cancer initiation, progression, and recurrence, thereby enabling exploration of novel therapeutic targets and biomarkers. CSCB basic, translational, and clinical researchers study normal stem cells and their malignant counterparts originating from two biological sources, hematopoiesis and epithelia. Scientific interactions between the two tissue platforms integrate by sharing common conceptual frameworks and experimental tools. The Program objective is to understand the intrinsic and extrinsic mechanisms that control homeostasis in healthy tissues that go awry in malignancy, and to harness these mechanisms for cancer treatment. Three specific aims guide achieving the Program objective. Aim 1- To understand how the biology of epithelial stem cells is regulated during malignant transformation and normal development. Aim 2- To define the mechanisms that regulate growth and differentiation of hematopoietic stem and progenitor cells during malignant transformation, normal development, and after transplantation. Aim 3- To determine the role of the microenvironment in tumor formation and stem cell regulation. The CSCB program has 36 faculty from 16 departments spanning four UCLA schools and affiliated institution Caltech, that together provide the breadth and depth of expertise needed to achieve scientific and programmatic goals. Program members are highly productive and collaborative with 633 cancer publications during the prior project period, 31% of which are inter-programmatic, 6% of which are intra-programmatic, and 44% of which are in high-impact (IF ≥10, or field leading) journals. Members have support from $11,389,786 in cancer funding, of which $2.7M (23%) is from the NCI and $8.1M (71%) is peer-reviewed. Program science is highly dependent on the JCCC, with significant member use of all six Shared Resources, the Seed and Impact grant programs, space allocations, and recruitment and retention of key investigators. Each CSCB investigator has a dominant interest in either hematopoietic or epithelial stem cells, although the shared biology of stem cells and cancer in all tissue types has led to an immensely fertile and interactive Program environment across platforms. These interactions benefit from a close collaboration between the JCCC and the UCLA Broad Stem Cell Research Center (BSCRC) over the past 12 years. Almost every investigator in CSCB works on at least two of the three specific aims, using combinations of animal model systems, human pluripotent stem cells, and primary human tissues to uncover basic biologic processes and reveal new opportunities for cancer treatment.

癌症与干细胞生物学研究计划(CSCB) 摘要 癌症和干细胞生物学研究计划(CSCB)由MBBS的Gay Crooks主任领导，他 专门从事造血干/祖细胞移植，医学博士Brigitte Gomperts联席主任，世卫组织 研究肺癌的发生和微环境的作用。CSCB将基本和翻译链接 研究人员研究干细胞和恶性肿瘤之间共有的生物过程。计划成员 期望对正常和异常细胞自我更新和 分化将揭示对癌症发生、发展和复发的新的生物学见解，从而 能够探索新的治疗靶点和生物标记物。CSCB基础版、翻译版和临床版 研究人员研究了来自两个生物来源的正常干细胞及其恶性对应细胞， 造血和上皮组织。两个组织平台之间的科学互动通过共享整合在一起 共同的概念框架和实验工具。该计划的目标是了解 以及控制在恶性肿瘤中出错的健康组织中的动态平衡的外部机制，并利用 癌症治疗的这些机制。三个具体目标指导实现计划目标。目标1--目标 了解上皮干细胞在癌变和正常过程中的生物学调控 发展。目的2-确定调节造血干细胞生长和分化的机制 和祖细胞在恶性转化、正常发育和移植后。目标3--至 确定微环境在肿瘤形成和干细胞调节中的作用。 CSCB项目有来自16个系的36名教师，横跨四所加州大学洛杉矶分校及其附属机构 加州理工学院，共同提供实现科学和规划所需的专业知识的广度和深度 目标。计划成员在前一年与633份癌症出版物合作，工作效率很高 项目期间，其中31%是方案间的，6%是方案内的，44%是方案内的 在高影响力(如果是≥10或领域领先的)期刊上。成员获得了11,389,786美元的癌症资金支持， 其中270万美元(23%)来自NCI，810万美元(71%)来自同行审查。程序科学高度依赖于 JCCC，成员大量使用所有六个共享资源、种子和影响赠款方案、空间 关键调查员的分配、招聘和留用。CSCB的每个调查员都有一个主要的利益 无论是造血干细胞还是上皮干细胞，尽管干细胞和所有组织中的癌症的共同生物学 Types带来了一个非常丰富的、跨平台的交互式程序环境。这些相互作用 受益于JCCC和加州大学洛杉矶分校广泛干细胞研究中心(BSCRC)之间的密切合作 在过去的12年里。CSCB的几乎每个调查员都至少致力于三个具体目标中的两个，使用 动物模型系统、人类多能干细胞和原代人体组织的组合 基本的生物过程，并揭示癌症治疗的新机会。